Published on 28/12/2025

How Patient Registries Support Safety and Outcomes Research in Phase 4 Clinical Trials

Introduction

Patient registries are organized systems that collect uniform data on a defined population over time. In Phase 4 clinical trials, registries offer unparalleled opportunities to track drug safety, effectiveness, adherence, and real-world outcomes in large and diverse patient populations. They serve as both standalone observational studies and data infrastructure for nested sub-studies.

Types of Registries Used in Phase 4

• Product Registries: Focus on patients taking a specific medicine
• Disease Registries: Track all patients with a condition regardless of therapy
• Pregnancy Registries: Monitor exposure and outcomes in pregnant populations
• Rare Disease Registries: Centralized data sources for orphan drug monitoring

Why Use Registries in Post-Marketing Studies?

• Longitudinal follow-up: Track outcomes over months or years
• Diverse populations: Capture real-world heterogeneity
• Data scalability: Build large datasets efficiently
• Regulatory alignment: PASS and REMS studies often require registries

Registry Components in Phase 4 Protocols

• Patient Enrollment Criteria: Broad eligibility with minimal exclusions
• Data Collection Forms (eCRF): Standardized, validated, and aligned with endpoints
• Follow-Up Intervals: Predefined visits or remote contact schedules
• Adverse Event Reporting: Linked to pharmacovigilance systems
• Quality Control: Site training, central monitoring, automated query resolution

Real-World Example: Gilenya Pregnancy Registry

Novartis initiated a global registry for women exposed to fingolimod during pregnancy.